Dreicer R. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol 2014;21(2 Suppl 1):93-7. Abstract

Edwina S et al. TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (bic) in men with metastatic castrate-resistant prostate cancer (CRPC). Proc ASCO 2012;Abstract TPS4698.

Fizazi K et al. Novel and bone-targeted agents for CRPC. Ann Oncol 2012;23(Suppl 10):x264-7. Abstract

Gomella LG et al. Current management of advanced and castration resistant prostate cancer. Can J Urol 2014;21(2 Suppl 1):1-6. Abstract

Hoskin P et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397-406. Abstract

Hurwitz M et al. Sequencing of agents for castration-resistant prostate cancer. Oncology (Williston Park) 2013;27(11):1144-9. Abstract

Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48. Abstract

Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97. Abstract